(3S)-1,1,1-trifluoro-3-methylpentane

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: (3S)-1,1,1-trifluoro-3-methylpentane
• 化学式: C₆H₁₁F₃
• 分子量: 140.15
• InChiKey: BJLHXROPECKRHX-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：UNIVERSAL DISPLAY CORPORATION

  公开号：US20200361974A1

  公开（公告）日：2020-11-19

  Provided are a compound having a metal M and a first ligand L A comprising the structure of where the compound is capable of functioning as a phosphorescent emitter in an organic light emitting device at room temperature.

  提供了一种化合物，该化合物含有金属M和具有所述结构的第一个配体LA，该化合物能够在室温下作为有机发光器件中的磷光发射体发挥作用。
• Organic electroluminescent materials and devices
  申请人：UNIVERSAL DISPLAY CORPORATION

  公开号：US20200308204A1

  公开（公告）日：2020-10-01

  A compound comprising a first bidentate ligand L A , wherein L A comprises a structure of Formula I; wherein Z is selected from the group consisting of O, S, NR, BR, CR K R L , SiR K R L , —CR K R L CR M R N —, —SiR K R L SiR M R N —, —CR K R L O—, —SiR K R L O—, and —CR K ═CR L —; wherein ring A, ring B, and ring C are each independently a 5-membered carbocyclic ring, 5-membered heterocyclic ring, 6-membered carbocyclic ring or 6-membered heterocyclic ring; wherein L A is coordinated to a metal M forming a 5-membered chelate ring; wherein M is selected from the group consisting of Ir, Pt, Pd, Ru, Rh, Os, Re, Cu, Ag, and Au; wherein R A , R B , and R C each represent mono to the maximum allowable substitution, or no substitution; wherein each R, R K , R L , R M , R N , R A , R B , and R C is independently a hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein M is optionally coordinated to one or more other ligands; wherein any two substituents are optionally joined or fused together to form a ring; and with the provision that L A does not comprise the following structure:

  一种化合物，包括第一双齿配体LA，其中LA包括结构式I的结构；其中Z选择自O、S、NR、BR、CRKRL、SiRKRL、—CRKRLCRMRN—、—SiRKRLSiRMRN—、—CRKRLO—、—SiRKRLO—和—CRK═CRL—组成的群体；其中环A、环B和环C分别独立为5元碳环、5元杂环、6元碳环或6元杂环；其中LA配位于金属M形成5元螯合环；其中M选择自Ir、Pt、Pd、Ru、Rh、Os、Re、Cu、Ag和Au组成的群体；其中RA、RB和RC分别表示单取代至最大允许取代，或无取代；其中每个R、RK、RL、RM、RN、RA、RB和RC独立地是氢或从氘、卤素、烷基、环烷基、杂原子烷基、芳基烷基、烷氧基、芳氧基、氨基、硅基、硼基、烯基、环烯基、杂原子烯基、炔基、芳基、杂芳基、酰基、羧酸、醚、酯、腈、异腈、硫基、亚硫基、砜基、膦基等组成的取代基中选择；其中M可以选择与一个或多个其他配体配位；其中任意两个取代基可以选择连接或融合在一起形成环；并且提供LA不包括以下结构：
• 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER
  申请人：Astrazeneca AB

  公开号：EP3640251A1

  公开（公告）日：2020-04-22

  The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.

  本说明书涉及式 (I) 化合物： 及其药学上可接受的盐、用于制备它们的工艺和中间体、含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。
• Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：US11370774B2

  公开（公告）日：2022-06-28

  Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  公开了式 I 和 II 的化合物及其药学上可接受的盐和原药，它们是补体系统的抑制剂。还提供了包含此类化合物的药物组合物，以及使用这些化合物和组合物治疗或预防以补体系统活性异常为特征的疾病或病症的方法。
• SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：US20210221786A1

  公开（公告）日：2021-07-22

  Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.